We are live on ! Find out more
GILD icon

Gilead Sciences

1,525 hedge funds and large institutions have $66.4B invested in Gilead Sciences in 2017 Q1 according to their latest regulatory filings, with 133 funds opening new positions, 601 increasing their positions, 701 reducing their positions, and 157 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.66% less ownership

Funds ownership: 75.43%74.76% (-0.66%)

3% less funds holding

Funds holding: 1,5731,525 (-48)

3% less funds holding in top 10

Funds holding in top 10: 9188 (-3)

7% less capital invested

Capital invested by funds: $71.2B → $66.4B (-$4.83B)

14% less repeat investments, than reductions

Existing positions increased: 601 | Existing positions reduced: 701

15% less first-time investments, than exits

New positions opened: 133 | Existing positions closed: 157

35% less call options, than puts

Call options by funds: $1.45B | Put options by funds: $2.24B

Holders
1,525
Holders Change
-48
Holders Change %
-3.05%
% of All Funds
37.95%
Holding in Top 10
88
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-3.3%
% of All Funds
2.19%
New
133
Increased
601
Reduced
701
Closed
157
Calls
$1.45B
Puts
$2.24B
Net Calls
-$793M
Net Calls Change
-$355M
Name Holding Trade Value Shares
Change
Change in
Stake
Jane Street
301
Jane Street
New York
$15.1M -$1.24M -17,637 -7%
Janney Montgomery Scott
302
Janney Montgomery Scott
Pennsylvania
$15.1M -$5.37M -76,318 -26%
XK
303
Xact Kapitalforvaltning
Sweden
$14.7M +$658K +9,360 +5%
DCM
304
Dupont Capital Management
Delaware
$14.7M -$2.25M -31,952 -13%
EAM
305
Edge Asset Management
Washington
$14.6M
APCM
306
Arbiter Partners Capital Management
New York
$14.6M +$5.63M +80,000 +59%
CAM
307
Capstone Asset Management
Texas
$14.6M +$921K +13,100 +6%
MAA
308
Matrix Asset Advisors
New York
$14.6M +$1.17M +16,632 +8%
DnB Asset Management
309
DnB Asset Management
Norway
$14.5M -$1.08M -15,300 -7%
CBOA
310
Commonwealth Bank of Australia
Australia
$14.5M +$3.56M +50,661 +31%
SW
311
SVB Wealth
Massachusetts
$14.5M +$940K +13,367 +7%
DP
312
Dearborn Partners
Illinois
$14.4M +$578K +8,214 +4%
SLAM
313
Swiss Life Asset Management
$14.4M +$9.02M +128,295 +154%
CCM
314
Cadence Capital Management
Massachusetts
$14.2M +$1.37M +19,462 +10%
Group One Trading
315
Group One Trading
Illinois
$14.1M +$2.29M +32,558 +19%
RPAM
316
Rhenman & Partners Asset Management
Sweden
$14.1M -$3.73M -52,978 -20%
TSW
317
Thompson Siegel & Walmsley
Virginia
$14.1M +$4.76M +67,758 +49%
NPPM
318
North Point Portfolio Managers
Ohio
$14M -$180K -2,565 -1%
ACPU
319
Arrowgrass Capital Partners (US)
Delaware
$13.9M +$9.39M +133,528 +188%
MOACM
320
Mutual of America Capital Management
New York
$13.7M +$829K +11,791 +6%
TAF
321
Tredje AP-fonden
Sweden
$13.6M -$92.3K -1,313 -0.7%
KCM
322
Kornitzer Capital Management
Kansas
$13.6M +$10.3M +146,706 +274%
Wolverine Trading
323
Wolverine Trading
Illinois
$13.4M +$2.51M +35,718 +22%
NG
324
NatWest Group
United Kingdom
$13.4M +$1M +14,273 +8%
CAI
325
Capital Advisors Inc
Oklahoma
$13.4M +$1.23M +17,534 +10%

GILD Hedge Fund Activity: Q1 2017 in Review

1,525 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Gilead Sciences (GILD) for Q1 2017, worth a combined $66.4B — down 6.8% from $71.2B a quarter earlier.

Sellers outnumbered buyers: 157 funds closed out of GILD and 133 opened new positions — a net loss of 24 holders — while 701 trimmed existing stakes and 601 added.

The largest buyer was BlackRock, adding an estimated $6.99B. The largest seller was Fidelity Investments, cutting an estimated $1.15B.

  • 1,525 institutional investors held Gilead Sciences (GILD) as of Q1 2017, down from 1,573 in Q4 2016.
  • Funds reported $66.4B of Gilead Sciences stock for Q1 2017, down 6.8% quarter-over-quarter.
  • 133 funds opened new Gilead Sciences positions in Q1 2017 and 157 closed out, a net change of -24 holders.
  • The largest Gilead Sciences buyer in Q1 2017 was BlackRock, an estimated $6.99B added.
  • The largest Gilead Sciences seller in Q1 2017 was Fidelity Investments, an estimated $1.15B sold.

Based on aggregated 13F filings for Q1 2017.